SG11202007055QA - Anti-claudin 18.2 antibodies and uses thereof - Google Patents
Anti-claudin 18.2 antibodies and uses thereofInfo
- Publication number
- SG11202007055QA SG11202007055QA SG11202007055QA SG11202007055QA SG11202007055QA SG 11202007055Q A SG11202007055Q A SG 11202007055QA SG 11202007055Q A SG11202007055Q A SG 11202007055QA SG 11202007055Q A SG11202007055Q A SG 11202007055QA SG 11202007055Q A SG11202007055Q A SG 11202007055QA
- Authority
- SG
- Singapore
- Prior art keywords
- claudin
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
- G01N33/6857—Antibody fragments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862640288P | 2018-03-08 | 2018-03-08 | |
| US201862714254P | 2018-08-03 | 2018-08-03 | |
| PCT/US2019/020872 WO2019173420A1 (en) | 2018-03-08 | 2019-03-06 | Anti-claudin 18.2 antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202007055QA true SG11202007055QA (en) | 2020-09-29 |
Family
ID=67847436
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202007055QA SG11202007055QA (en) | 2018-03-08 | 2019-03-06 | Anti-claudin 18.2 antibodies and uses thereof |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11555070B2 (en) |
| EP (1) | EP3762031A4 (en) |
| JP (1) | JP7398380B2 (en) |
| KR (1) | KR20200129116A (en) |
| CN (1) | CN111836644A (en) |
| AU (1) | AU2019232762B2 (en) |
| BR (1) | BR112020015479A2 (en) |
| CA (1) | CA3089653A1 (en) |
| IL (1) | IL276830A (en) |
| MX (1) | MX2020009326A (en) |
| SG (1) | SG11202007055QA (en) |
| WO (1) | WO2019173420A1 (en) |
| ZA (1) | ZA202004730B (en) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210134321A (en) | 2019-02-01 | 2021-11-09 | 노바록 바이오테라퓨틱스 리미티드 | Anti-claudin 18 antibodies and methods of use thereof |
| AU2020253792A1 (en) * | 2019-03-29 | 2021-09-09 | Phanes Therapeutics, Inc. | Humanized anti-claudin 18.2 chimeric antigen receptors and uses thereof |
| WO2021003082A1 (en) * | 2019-07-03 | 2021-01-07 | Phanes Therapeutics, Inc. | Anti-claudin 18.2/anti-cd47 bispecific antibodies and uses thereof |
| TW202124442A (en) * | 2019-09-13 | 2021-07-01 | 大陸商北京軒義醫藥科技有限公司 | Humanized anti-cldn18.2 antibodies, nucleic acid molecules encoding the same, method of producing the same, composition comprising the same, kit and the use thereof |
| CN112707965A (en) * | 2019-09-30 | 2021-04-27 | 和铂医药(苏州)有限公司 | Antibody targeting CLDN18.2 and preparation method and application thereof |
| CA3159465A1 (en) | 2019-12-06 | 2021-06-10 | Lukas BAMMERT | Humanized cldn18.2 antibodies |
| KR20220119117A (en) | 2019-12-23 | 2022-08-26 | 소티오 바이오테크 에이.에스. | Tumor specific CLAUDIN 18.2 antibody |
| WO2021136550A1 (en) * | 2020-01-03 | 2021-07-08 | 佧珐药业有限公司 | Anti-claudin 18.2 antibody and use thereof |
| WO2021143934A1 (en) * | 2020-01-19 | 2021-07-22 | Nanjing GenScript Biotech Co., Ltd. | Multispecific anti-claudin-18.2 constructs and uses thereof |
| KR20220139357A (en) * | 2020-02-10 | 2022-10-14 | 상하이 에스쿠겐 바이오테크놀로지 컴퍼니 리미티드 | CLDN18.2 Antibodies and Their Uses |
| JP2023513401A (en) * | 2020-02-10 | 2023-03-30 | 上海詩健生物科技有限公司 | Antibodies to claudin 18.2 and uses thereof |
| US20230002486A1 (en) * | 2020-06-18 | 2023-01-05 | Sparx Therapeutics, Inc. | Bispecific antibodies targeting human claudin 18.2 and programmed death-ligand 1 (pd-l1) |
| JP2023544140A (en) * | 2020-09-28 | 2023-10-20 | エルピサイエンス（スーチョウ）・バイオファーマ，リミテッド | Novel anti-claudin 18 antibody |
| CN112480248B (en) * | 2020-11-24 | 2023-05-05 | 三优生物医药(上海)有限公司 | Molecules that specifically bind to CLD18A2 |
| WO2022122709A1 (en) | 2020-12-07 | 2022-06-16 | Sotio Biotech A.S. | Antibody-drug conjugates based on humanized cldn18.2 antibodies |
| AU2021405049A1 (en) | 2020-12-23 | 2023-06-22 | Sotio Biotech A.S. | Tumor-specific claudin 18.2 antibody-drug conjugates |
| CN113321730B (en) * | 2021-01-11 | 2023-10-10 | 上海莱馥医疗科技有限公司 | CLDN18.2 antibodies and uses thereof |
| CN114805571B (en) * | 2021-01-28 | 2023-08-25 | 广西鹭港生物医药科技有限公司 | anti-CLDN 18.2 antibodies and uses thereof |
| CN112940124B (en) * | 2021-04-14 | 2022-04-05 | 南京凯地医疗技术有限公司 | Humanized monoclonal antibody targeting Claudin18.2 and preparation method and application thereof |
| CN112979817B (en) * | 2021-04-27 | 2021-08-13 | 宝船生物医药科技(上海)有限公司 | Monoclonal antibody for recognizing anti-CLDN 18_2 antibody and preparation method and application thereof |
| CA3220891A1 (en) * | 2021-05-31 | 2022-12-08 | Zhenhua Jia | Monoclonal antibodies against cldn18.2 and fc-engineered versions thereof |
| CN116102649A (en) * | 2021-11-11 | 2023-05-12 | 上海生物制品研究所有限责任公司 | anti-CLDN 18.2 monoclonal antibody and application thereof |
| WO2023240086A1 (en) * | 2022-06-07 | 2023-12-14 | Unm Rainforest Innovations | Humanized non-opioid composition and therapies for pain management |
| CN117229398A (en) * | 2022-06-15 | 2023-12-15 | 中山康方生物医药有限公司 | anti-CLDN 18.2 antibody, pharmaceutical composition and use thereof |
| WO2024002257A1 (en) * | 2022-06-30 | 2024-01-04 | Suzhou Transcenta Therapeutics Co., Ltd. | Stable pharmaceutical formulation comprising an anti-cldn18.2 antibody |
| CN117777288A (en) * | 2022-09-29 | 2024-03-29 | 南京博望医药科技有限公司 | Antibodies against claudin 18.2 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1790664A1 (en) | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
| EP1914242A1 (en) * | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| EP1997832A1 (en) * | 2007-05-29 | 2008-12-03 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against Claudin-18 for treatment of cancer |
| EP2547695B1 (en) | 2010-03-16 | 2018-05-09 | Biontech Protein Therapeutics GmbH | Tumor vaccination involving a humoral immune response against self-protein cldn18.2 |
| WO2013167153A1 (en) * | 2012-05-09 | 2013-11-14 | Ganymed Pharmaceuticals Ag | Antibodies useful in cancer diagnosis |
| WO2013174404A1 (en) | 2012-05-23 | 2013-11-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| WO2013174403A1 (en) | 2012-05-23 | 2013-11-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| WO2014075697A1 (en) | 2012-11-13 | 2014-05-22 | Biontech Ag | Agents for treatment of claudin expressing cancer diseases |
| KR102643443B1 (en) | 2012-11-13 | 2024-03-06 | 비온테크 에스이 | Agents for treatment of claudin expressing cancer diseases |
| WO2014127785A1 (en) | 2013-02-20 | 2014-08-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| WO2014146672A1 (en) | 2013-03-18 | 2014-09-25 | Ganymed Pharmaceuticals Ag | Therapy involving antibodies against claudin 18.2 for treatment of cancer |
| PL2976360T3 (en) * | 2013-03-18 | 2020-05-18 | Astellas Pharma Inc. | Therapy involving antibodies against claudin 18.2 for treatment of cancer |
| WO2015113576A1 (en) | 2014-01-29 | 2015-08-06 | Biontech Ag | Peptide mimotopes of claudin 18.2 and uses thereof |
| WO2016165765A1 (en) | 2015-04-15 | 2016-10-20 | Ganymed Pharmaceuticals Ag | Methods and compositions for prediction of therapeutic efficacy of cancer treatments and cancer prognosis |
| WO2016165762A1 (en) | 2015-04-15 | 2016-10-20 | Ganymed Pharmaceuticals Ag | Drug conjugates comprising antibodies against claudin 18.2 |
| WO2016180467A1 (en) * | 2015-05-11 | 2016-11-17 | Biontech Cell & Gene Therapies Gmbh | Enhancing the effect of car-engineered t cells by means of nucleic acid vaccination |
| WO2016180468A1 (en) | 2015-05-11 | 2016-11-17 | Biontech Cell & Gene Therapies Gmbh | Claudin-18.2-specific immunoreceptors and t cell epitopes |
| SG11201808911SA (en) * | 2016-04-13 | 2018-11-29 | Sanofi Sa | Trispecific and/or trivalent binding proteins |
| KR20190038564A (en) | 2016-07-08 | 2019-04-08 | 카르스젠 테라퓨틱스 컴퍼니, 리미티드 | Antibodies to Anti-Claudine 18A2 and its Application |
-
2019
- 2019-03-06 AU AU2019232762A patent/AU2019232762B2/en active Active
- 2019-03-06 EP EP19764603.7A patent/EP3762031A4/en active Pending
- 2019-03-06 SG SG11202007055QA patent/SG11202007055QA/en unknown
- 2019-03-06 CN CN201980018057.5A patent/CN111836644A/en active Pending
- 2019-03-06 CA CA3089653A patent/CA3089653A1/en active Pending
- 2019-03-06 WO PCT/US2019/020872 patent/WO2019173420A1/en active Application Filing
- 2019-03-06 US US15/733,553 patent/US11555070B2/en active Active
- 2019-03-06 KR KR1020207027632A patent/KR20200129116A/en not_active Application Discontinuation
- 2019-03-06 JP JP2020546942A patent/JP7398380B2/en active Active
- 2019-03-06 BR BR112020015479-2A patent/BR112020015479A2/en unknown
- 2019-03-06 MX MX2020009326A patent/MX2020009326A/en unknown
-
2020
- 2020-07-30 ZA ZA2020/04730A patent/ZA202004730B/en unknown
- 2020-08-20 IL IL276830A patent/IL276830A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019232762B2 (en) | 2023-11-16 |
| CA3089653A1 (en) | 2019-09-12 |
| JP7398380B2 (en) | 2023-12-14 |
| US11555070B2 (en) | 2023-01-17 |
| KR20200129116A (en) | 2020-11-17 |
| JP2021514664A (en) | 2021-06-17 |
| EP3762031A4 (en) | 2021-12-22 |
| IL276830A (en) | 2020-10-29 |
| US20200399364A1 (en) | 2020-12-24 |
| ZA202004730B (en) | 2024-01-31 |
| CN111836644A (en) | 2020-10-27 |
| AU2019232762A1 (en) | 2020-08-27 |
| EP3762031A1 (en) | 2021-01-13 |
| BR112020015479A2 (en) | 2020-12-08 |
| MX2020009326A (en) | 2020-10-08 |
| WO2019173420A1 (en) | 2019-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL276830A (en) | Anti-claudin 18.2 antibodies and uses thereof | |
| SG10202111141WA (en) | Anti-claudin 18.2 antibodies and uses thereof | |
| EP3878863A4 (en) | Anti-claudin18.2 antibody and use thereof | |
| IL277072A (en) | Anti-claudin 18.2 antibodies | |
| ZA202103061B (en) | Anti-cldn18.2 antibody and uses thereof | |
| IL276950A (en) | Anti-cd73 antibodies and uses thereof | |
| ZA202106880B (en) | Anti-claudin 18.2 antibody and application thereof | |
| IL282968A (en) | Anti-nkg2a antibodies and uses thereof | |
| SG11202105885WA (en) | Anti-claudin antibodies and uses thereof | |
| IL275826A (en) | Anti-mct1 antibodies and uses thereof | |
| IL289585A (en) | Dll3-targeting antibodies and uses thereof | |
| IL281297A (en) | Anti-npr1 antibodies and uses thereof | |
| SG11202009772PA (en) | Anti-dll3 antibodies and uses thereof | |
| SG11202009625WA (en) | Anti-trem-1 antibodies and uses thereof | |
| EP3692072A4 (en) | Anti-hla-dq2.5 antibody | |
| IL280321A (en) | Anti-cxcr2 antibodies and uses thereof | |
| IL277330A (en) | Anti-il-27 antibodies and uses thereof | |
| IL283875A (en) | Anti-il-27 antibodies and uses thereof | |
| IL277075A (en) | Anti-phf-tau antibodies and uses thereof | |
| IL276548A (en) | Bcma-binding antibodies and uses thereof | |
| IL291027A (en) | Anti-steap1 antibodies and uses thereof | |
| IL283926A (en) | Anti-alpha-synuclein antibodies and uses thereof | |
| IL281202A (en) | Anti-tnfrsf9 antibodies and uses thereof | |
| IL283890A (en) | Anti-periostin antibodies and uses thereof | |
| EP4041403A4 (en) | Anti-kir3dl3 antibodies and uses thereof |